Answers are grounded in this paper and cite their sources.
To the editor: In late December 2016, Seattle Genetics, Inc., announced that the US Food and Drug Administration (FDA) had placed a hold or partial hold on several early-stage clinical trials of vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia (AML) to further evaluate the potential risk
No takes yet. Share an insight, caveat, or question.
Godwin et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: